Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, some people do lose weight on 2.5mg Mounjaro, but this dose is designed primarily to help your body adjust to tirzepatide rather than to deliver the full weight-loss effect. Clinical trials published in the New England Journal of Medicine (SURMOUNT-1) showed average reductions of around 20% of body weight at the highest maintenance doses — results that build over months, beginning from this exact starting point. The 2.5mg strength is where everyone begins; what happens at that dose is a little more nuanced than a simple yes or no. Mounjaro is a prescription-only medicine, so whether it is right for you is decided by a prescriber following a clinical assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, conducted over 72 weeks and involving 2,539 adults with obesity, tested tirzepatide at 5mg, 10mg and 15mg maintenance doses, not 2.5mg. That is deliberate. The 2.5mg dose was the universal four-week lead-in: every participant began there before moving up. The trial's headline figures (roughly 15% average weight loss at 5mg, rising to around 20–21% at 15mg) were measured after the full titration journey, not after the starter phase alone. So the evidence base does not give us a standalone 2.5mg weight-loss figure, because that was never the dose being tested as a therapeutic endpoint. What it does tell us is that the trajectory begins here. The NHS tirzepatide page describes 2.5mg plainly as the dose used at the start of treatment to reduce the chance of side effects, specifically the nausea and digestive discomfort that tend to be most pronounced when GLP-1 and GIP receptors are first activated. The medicine is already working at 2.5mg: appetite signals shift, gastric emptying slows, and many people notice they feel full sooner at meals. For some, those changes are enough to produce modest but measurable weight loss within the first four weeks, and if you are curious whether moving to 5mg is where more meaningful weight loss begins, that question has its own dedicated answer. For others, the effect at this dose is subtle, and that is equally normal.
The honest answer is: often, yes, but not always, and not as much as you will likely see later. Anecdotally, many people report losing a small amount of weight during their first four weeks on 2.5mg, typically driven by reduced appetite and smaller portion sizes rather than any dramatic physiological shift. Others notice little change on the scale, particularly if fluid retention, water weight fluctuations or a delayed appetite response means the medicine has not yet made a strong impression on hunger. Neither outcome is a sign that treatment is failing. The dose's job is adjustment, not acceleration. If you want to understand whether you lose more weight on 5mg Mounjaro than on 2.5mg, that comparison is covered in detail on its own page. One simple habit worth building now: weigh yourself on the same day each week, at the same time of day, wearing roughly the same clothing. A single weekly snapshot is far more useful than daily readings, which swing with hydration, salt intake and hormones. That one-minute ritual will give you and your prescriber far better data when they review your progress.
Some people wonder whether remaining at 2.5mg for longer than the standard four weeks would produce more weight loss before moving up. The licensed titration schedule exists for good reason: higher doses are where the greater clinical effect is documented, and most people tolerate the step increases well when they follow the gradual schedule. Staying at 2.5mg indefinitely is not the same as being on a therapeutic weight-management dose. That said, titration pace is always a clinical judgement. If side effects are making a dose increase difficult, a prescriber may extend the time at a given level, this is a conversation to have directly with them, not something to decide alone. The question of whether staying on 2.5mg long-term can support weight loss is one our prescribers discuss with patients regularly. For context on how the numbers change as the dose rises, our full guide to Mounjaro 5mg is worth reading alongside this page, and if you want a direct look at how the outcomes compare, the comparison between 2.5mg and 5mg results answers that question in detail. Mounjaro is not the only injectable option; our weight-loss treatment overview sets out the medicines licensed in the UK and what each one involves. All treatment decisions at nume sit with a named prescriber, not a decision engine, a real clinician reads your consultation the same day. If you are weighing up whether to start, a free consultation is the straightforward next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.